Silvercrest Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Silvercrest Asset Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$582K	Sell	4,560 -300	-6%	-$37.5K	﹤0.01%	663
2025 Q4	$593K	Hold	4,860	–	–	﹤0.01%	696
2025 Q3	$487K	Sell	4,860 -500	-9%	-$45K	﹤0.01%	700
2025 Q2	$445K	Sell	5,360 -225	-4%	-$17.9K	﹤0.01%	724
2025 Q1	$453K	Sell	5,585 -350	-6%	-$31.3K	﹤0.01%	717
2024 Q4	$535K	Buy	5,935 +100	+2%	+$9.69K	﹤0.01%	681
2024 Q3	$576K	Hold	5,835	–	–	﹤0.01%	635
2024 Q2	$541K	Hold	5,835	–	–	﹤0.01%	705
2024 Q1	$554K	Buy	5,835 +10	+0.2%	+$928	﹤0.01%	691
2023 Q4	$520K	Hold	5,825	–	–	﹤0.01%	658
2023 Q3	$425K	Hold	5,825	–	–	﹤0.01%	700
2023 Q2	$485K	Hold	5,825	–	–	﹤0.01%	680
2023 Q1	$444K	Buy	+5,825	New	+$483K	﹤0.01%	667

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Silvercrest Asset Management's XBI Position: Q1 2026 in Review

Silvercrest Asset Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 6.2% in Q1 2026, selling an estimated $37.5K and leaving 4,560 shares worth $582K. The position accounts for ﹤0.01% of the portfolio, ranked #663.

Silvercrest Asset Management first reported a position in XBI in Q1 2023 and has held it in 13 quarters since. The position peaked at $593K in Q4 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Silvercrest Asset Management held 4,560 shares of State Street SPDR S&P Biotech ETF worth $582K as of Q1 2026.
Silvercrest Asset Management sold 300 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $37.5K.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Silvercrest Asset Management's portfolio in Q1 2026, its #663 holding.
Silvercrest Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2023 and has held it in 13 quarters since.
Silvercrest Asset Management's State Street SPDR S&P Biotech ETF position peaked at $593K in Q4 2025.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Silvercrest Asset Management's 13F filing for Q1 2026, filed 15 May 2026.